Humira: The First $20 Billion Drug

Jason B. Gibbons; Micaela Laber; Charles L. Bennett

doi:10.37765/ajmc.2023.89315

Humira: The First $20 Billion Drug

Jason B. Gibbons, Micaela Laber, Charles L. Bennett

Research output: Contribution to journal › Review article › peer-review

Abstract

AbbVie’s adalimumab (Humira) is the top-selling pharmaceutical in the world. Due to concerns about government health program spending on Humira, the US House Committee on Oversight and Accountability opened an investigation in 2019 to investigate AbbVie’s pricing and marketing practices. We review these reports and describe policy debates surrounding the highest-grossing drug to highlight how the legal landscape enables incumbent manufacturers to block competition in the pharmaceutical market. Tactics include patent thickets, evergreening, Paragraph IV settlement agreements, product hopping, and linking executive compensation to sales growth. These strategies are not unique to AbbVie and shed light on pharmaceutical market dynamics that may be hindering a competitive market. Policy reform and legal initiatives may help reduce anticompetitive behaviors by pharmaceutical manufacturers and increase access to competitive therapeutic options such as biosimilars.

Original language	English (US)
Pages (from-to)	78-80
Number of pages	3
Journal	American Journal of Managed Care
Volume	29
Issue number	2
DOIs	https://doi.org/10.37765/ajmc.2023.89315
State	Published - Feb 2023
Externally published	Yes

ASJC Scopus subject areas

Health Policy

Access to Document

10.37765/ajmc.2023.89315

Cite this

@article{64fa92a4099d43a6a2d18d4d895d41a3,

title = "Humira: The First $20 Billion Drug",

abstract = "AbbVie{\textquoteright}s adalimumab (Humira) is the top-selling pharmaceutical in the world. Due to concerns about government health program spending on Humira, the US House Committee on Oversight and Accountability opened an investigation in 2019 to investigate AbbVie{\textquoteright}s pricing and marketing practices. We review these reports and describe policy debates surrounding the highest-grossing drug to highlight how the legal landscape enables incumbent manufacturers to block competition in the pharmaceutical market. Tactics include patent thickets, evergreening, Paragraph IV settlement agreements, product hopping, and linking executive compensation to sales growth. These strategies are not unique to AbbVie and shed light on pharmaceutical market dynamics that may be hindering a competitive market. Policy reform and legal initiatives may help reduce anticompetitive behaviors by pharmaceutical manufacturers and increase access to competitive therapeutic options such as biosimilars.",

author = "Gibbons, {Jason B.} and Micaela Laber and Bennett, {Charles L.}",

year = "2023",

month = feb,

doi = "10.37765/ajmc.2023.89315",

language = "English (US)",

volume = "29",

pages = "78--80",

journal = "American Journal of Managed Care",

issn = "1088-0224",

publisher = "Ascend Media",

number = "2",

}

TY - JOUR

T1 - Humira

T2 - The First $20 Billion Drug

AU - Gibbons, Jason B.

AU - Laber, Micaela

AU - Bennett, Charles L.

PY - 2023/2

Y1 - 2023/2

N2 - AbbVie’s adalimumab (Humira) is the top-selling pharmaceutical in the world. Due to concerns about government health program spending on Humira, the US House Committee on Oversight and Accountability opened an investigation in 2019 to investigate AbbVie’s pricing and marketing practices. We review these reports and describe policy debates surrounding the highest-grossing drug to highlight how the legal landscape enables incumbent manufacturers to block competition in the pharmaceutical market. Tactics include patent thickets, evergreening, Paragraph IV settlement agreements, product hopping, and linking executive compensation to sales growth. These strategies are not unique to AbbVie and shed light on pharmaceutical market dynamics that may be hindering a competitive market. Policy reform and legal initiatives may help reduce anticompetitive behaviors by pharmaceutical manufacturers and increase access to competitive therapeutic options such as biosimilars.

AB - AbbVie’s adalimumab (Humira) is the top-selling pharmaceutical in the world. Due to concerns about government health program spending on Humira, the US House Committee on Oversight and Accountability opened an investigation in 2019 to investigate AbbVie’s pricing and marketing practices. We review these reports and describe policy debates surrounding the highest-grossing drug to highlight how the legal landscape enables incumbent manufacturers to block competition in the pharmaceutical market. Tactics include patent thickets, evergreening, Paragraph IV settlement agreements, product hopping, and linking executive compensation to sales growth. These strategies are not unique to AbbVie and shed light on pharmaceutical market dynamics that may be hindering a competitive market. Policy reform and legal initiatives may help reduce anticompetitive behaviors by pharmaceutical manufacturers and increase access to competitive therapeutic options such as biosimilars.

UR - http://www.scopus.com/inward/record.url?scp=85148549388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85148549388&partnerID=8YFLogxK

U2 - 10.37765/ajmc.2023.89315

DO - 10.37765/ajmc.2023.89315

M3 - Review article

C2 - 36811981

AN - SCOPUS:85148549388

SN - 1088-0224

VL - 29

SP - 78

EP - 80

JO - American Journal of Managed Care

JF - American Journal of Managed Care

IS - 2

ER -

Humira: The First $20 Billion Drug

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this